A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Reduction of angiogenesis in chorioallantoic membrane xenografted hepatocellular carcinomas by treatment with a decorin-expressing herpes simplex virus vector
Tekijät: Frejborg, Fanny; Koivisto, Oliver; Huttunen, Roope; Rosenholm, Jessica M.; Zhang, Hongbo; Järveläinen, Hannu; Hukkanen, Veijo
Julkaisuvuosi: 2026
Lehti: Virology Journal
eISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-026-03162-w
Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla
Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava
Verkko-osoite: https://doi.org/10.1186/s12985-026-03162-w
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/523107626
Rinnakkaistallenteen lisenssi: CC BY
Rinnakkaistallennetun julkaisun versio: Kustantajan versio
Decorin is a proteoglycan that suppresses tumor growth and angiogenesis. We studied whether our recently constructed decorin-expressing herpes simplex virus (HSV) vector can reduce angiogenesis in xenografted liver carcinoma cells in the chorioallantoic membrane model. The vascularized tumors were treated with an overlay dose of our vector. The results show that the treatment reduced angiogenesis in the tumors by 60% (p = 0.005) four days after treatment, suggesting that decorin-expressing HSV vectors are a promising strategy for novel cancer therapies.
Julkaisussa olevat rahoitustiedot:
F. F. would like to thank Åbo Akademi University Graduate School for personal funding in the form of PhD salary. The authors would further like to thank the Jane and Aatos Erkko Foundation (#170046), Satasairaala Central Hospital, The Wellbeing Services County of Satakunta, Cancer Foundation of Southwestern Finland, State of Finland Research Fund (VTR), Research Council of Finland (project numbers #337531, #347897, #353146), Sigrid Jusélius foundation, The Paulo Foundation and Turku University foundation for funding this project. This research is also aligned with the strategic research profiling area “Solutions for Health” at Åbo Akademi University (funded by the Research Council of Finland, #336355).
